| | | >>I am tempted to call up and ask if they are seeing any interest in their CD200 program, or if they are talking to anyone at all about it. They keep not talking about it publicly, so is it dead?<<
The purchase of a discovery stage private company strengthens the suggestion that the CD200 program is dead. These folks knew each other. A Trillium SAB member co-authored at least one paper with Fluorinov folks. So hopefully, less bias than scientific acumen in choosing this deal.
Anyhow, with no partners or income, this suggests a financing in the offing. Unless they simply think they can auction off the stuff for more than they paid. But my gut says Trillium doesn't currently have that sort of of business development mojo.
Not going to add anymore to my re-starter position until the financing comes, unless something drastic happens.
Meanwhile, we get a bunch more stuff to research, to see if there any gems in this new portfolio of of pre-IND stuff. Sigh.
H/T to dewophile on IHub for starting that process:
Bromodomain inhibitor for AML
OTX015, upon which this compound is supposed to be an improvement, is now at Merck.
Cheers, Tuck |
|
